TrialAssure to lead EU CTR anonymisation workshop at PHUSE EU Connect 2026

TrialAssure will host a hands-on workshop in Glasgow on Nov. 16 for sponsors and CROs navigating clinical document disclosure under the EU Clinical Trials Regulation. The session is designed to help attendees make defensible anonymisation decisions for materials published through CTIS.

Why it matters: - Sponsors and contract research organizations are under growing pressure to balance transparency with patient privacy and commercially confidential information in documents published through the Clinical Trials Information System. - The workshop is built around practical decision-making, which could help teams reduce both over-redaction and under-redaction in public disclosures.

What happened: - TrialAssure said Zach Weingarden, director of AI technology and applications, and James Greene, executive leader for growth and partnerships, will lead an interactive workshop at PHUSE EU Connect 2026 in Glasgow, Scotland. - The session, titled “Redact, Protect, Disclose: A Practical Workshop on Clinical Document Anonymisation under EU CTR,” is set for Monday, Nov. 16, from 16:00 to 17:30 GMT in Room M2-4. - TrialAssure positioned the workshop as a hands-on session for sponsors and CROs dealing with disclosure requirements under EU Clinical Trials Regulation No. 536/2014.

The details: - The 90-minute workshop will put participants into small groups to work through realistic scenarios involving protocol excerpts, clinical study reports and patient narratives. - Participants will identify personal data and commercially confidential information that need protection. - Participants will apply regulatory guidance to anonymisation decisions. - Participants will evaluate the consequences of excessive redaction and insufficient redaction. - Participants will compare interpretations with peers and defend their decisions in group discussion. - Participants will work on practical decision-making frameworks they can use in future disclosure activities. - Greene said the workshop is meant to help attendees compare decisions with other professionals and develop approaches they can apply inside their own organizations. - Weingarden said the goal is for attendees to leave with greater confidence in their decisions and a practical understanding of difficult public disclosure scenarios. - TrialAssure said the session will draw on its experience supporting clinical document anonymisation across pharmaceutical and CRO programs. - TrialAssure’s ANONYMIZE® technology supports risk-based anonymisation and redaction across clinical documents, datasets and images. - The company said the technology is designed to help organizations balance privacy protection with the utility of disclosed information. - PHUSE EU Connect brings together professionals in clinical data science, statistical programming and related fields.

Between the lines: - EU CTR No. 536/2014 is now fully implemented, and the shift away from the previous Clinical Trials Directive has made disclosure decisions more operationally complex. - The workshop emphasis on judgment and defensible decisions suggests the field still lacks a single, simple standard for anonymising clinical documents in every case. - TrialAssure is using the event to highlight its software and services in a compliance area where manual review and expert interpretation still matter. - More information is available through the workshop listing and TrialAssure’s website.

What’s next: - PHUSE EU Connect 2026 will host the workshop on Nov. 16 in Glasgow. - Attendees who want to participate can sign up through the event page. - TrialAssure is directing interested readers to its newly launched website for additional product information.

The bottom line: - TrialAssure is betting that practical, scenario-based training will help sponsors and CROs make stronger anonymisation choices as EU clinical disclosure requirements continue to tighten.